Side-by-side · Research reference
LivagenvsMazdutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BPhase 3HUMAN-REVIEWED19/62 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
Livagen
Mazdutide
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Feedback intact?
—
Yes — physiological receptor-mediated signaling preserved
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
Mazdutide
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
SubcutaneousJi 2026
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Human data
None in provided literature
—
Phase 2 studied dose
—
Dose escalation
—
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
Duration (trials)
—
24–48 weeks
Population
—
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
03Metabolic / Fat Loss Evidence
Parameter
Livagen
Mazdutide
Percentage body weight loss
—
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
Responder rate (≥10% loss)
—
Not explicitly reported in available abstracts
Visceral fat
—
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
Glycemic improvement
—
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
Key publications
—
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
04Side Effects & Safety
Parameter
Livagen
Mazdutide
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
—
Gastrointestinal symptoms
—
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
Injection site reactions
—
Erythema, pruritus, local discomfort
Hypoglycemia
—
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
Cardiovascular effects
—
Increased heart rate (glucagon effect, transient)
Pancreatitis risk
—
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
Thyroid C-cell tumors
—
Black box warning for GLP-1 class (rodent data); human relevance unclear
Gallbladder disease
—
Cholelithiasis, cholecystitis (rapid weight loss effect)
Tolerability
—
Generally well-tolerated; GI effects diminish with dose titration
Absolute Contraindications
Livagen
—Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Relative Contraindications
Livagen
—Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
05Administration Protocol
Parameter
Livagen
Mazdutide
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
4. Storage
—
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
5. Needle technique
—
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.